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Abstract
 
The mechanism of CD4
 

 
 T cell depletion in human immunodeficiency virus (HIV)-1 infection
remains controversial. Using deuterated glucose to label the DNA of proliferating cells in vivo,
we studied T cell dynamics in four normal subjects and seven HIV-1–infected patients naive to
antiretroviral drugs. The results were analyzed using a newly developed mathematical model to
determine fractional rates of lymphocyte proliferation and death. In CD4
 

 
 T cells, mean prolif-
eration and death rates were elevated by 6.3- and 2.9-fold, respectively, in infected patients
compared with normal controls. In CD8
 

 
 T cells, the mean proliferation rate was 7.7-fold
higher in HIV-1 infection, but the mean death rate was not significantly increased. Five of the
infected patients underwent subsequent deuterated glucose labeling studies after initiating anti-
retroviral therapy. The lymphocyte proliferation and death rates in both CD4
 

 
 and CD8
 

 
 cell
populations were substantially reduced by 5–11 weeks and nearly normal by one year. Taken
together, these new findings strongly indicate that CD4
 

 
 lymphocyte depletion seen in AIDS is
primarily a consequence of increased cellular destruction, not decreased cellular production.
Key words: deuterated glucose • longitudinal study • mathematical model • apoptosis • 
mechanisms of CD4
 

 
 T cell depletion
 
Introduction
 
CD4
 

 
 
 
lymphocyte depletion, the immunologic hallmark of
AIDS, may be the consequence of HIV-1’s ability to in-
crease cellular destruction, decrease cellular production, or
both. This important, unresolved issue was initially ad-
dressed by quantifying the rebound in CD4
 

 
 T cells during
effective antiretroviral therapy (1, 2). The observed rapid
rise in such cell counts in blood provided indirect evidence
that CD4
 

 
 lymphocytes were turning over at a high rate
during HIV-1 infection. However, this conclusion was
called into question by the possibility that the rise could be
largely due to lymphocyte redistribution (3). That telomere
lengths in CD4
 

 
 T cells of infected persons remained rela-
tively stable over time further argued against a discernible
increase in lymphocyte turnover (4), a conclusion contra-
dicted by findings of higher frequencies of T cells express-
ing proliferation antigens in HIV-1 infection (5, 6). Direct
measurement of lymphocyte dynamics was then performed
using bromodeoxyuridine to label proliferating cells in
macaques with and without simian immunodeficiency virus
(SIV) infection (7, 8). Conclusive data emerged that show
turnover rates for both CD4
 

 
 and CD8
 

 
 lymphocytes to be
several-fold faster in SIV infection. More recently, a label-
ing technique using deuterated glucose (D-glucose)
 
*
 
 was
developed to safely quantify T cell dynamics in humans (9).
 
The preliminary results of this study were presented at the 7th Confer-
ence on Retroviruses and Opportunistic Infections from January 30–Feb-
ruary 2, 2000, San Francisco, CA (abstract #652) and at the 8th Confer-
ence on Retroviruses and Opportunistic Infections from February 4–8,
2001, Chicago, IL (abstract #269).
L. Weinberger’s current address is Biophysics Graduate Group, Uni-
versity of California, Berkeley, CA 94720.
Address correspondence to David D. Ho, Aaron Diamond AIDS Re-
search Center, 455 First Ave., New York, NY 10016. Phone: 212-448-
5100; Fax: 212-725-1126; E-mail: dho@adarc.org
 
 
 
*
 
Abbreviations used in this paper:
 
 dA, deoxyadenosine; D-glucose, deuter-
ated glucose; TUNEL, TdT-mediated dUTP nick-end labeling; SIV,
simian immunodeficiency virus; TREC, T cell receptor excision circles.
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Its initial application demonstrated enhanced CD4
 

 
 and
CD8
 

 
 lymphocyte turnover in HIV-1 infection (10).
However, that these rates were even higher in patients suc-
cessfully treated with antiretroviral therapy (10) was inter-
preted by some (11, 12) to suggest a block in lymphocyte
production as the major dysfunction caused by HIV-1. To
resolve these apparent conflicts, we conducted a detailed
study using D-glucose labeling in normal subjects as well as
in HIV-1–infected patients before and during treatment.
The results were then analyzed with a newly developed
mathematical model. We now report that both CD4
 

 
 and
CD8
 

 
 
 
lymphocyte turnover rates are elevated several-fold
in HIV-1 infection, and these rates begin to normalize
within a few months of effective antiretroviral therapy.
 
Materials and Methods
 
Study Subjects.
 
Four normal persons and seven HIV-1–infected
but untreated patients were recruited into the study (Table I).
Each study subject gave informed consent to participating in a
clinical protocol, which was approved by the Institutional Re-
view Board of The Rockefeller University Hospital. Five of the
infected individuals were given antiretroviral therapy several
weeks after the completion of the first D-glucose labeling study.
The treatment regimen consisted of nelfinavir (2,500 mg/d),
lamivudine (300 mg/d), abacavir (600 mg/d), and efavirenz (600
mg/d). Drug substitutions were permitted for intolerance or ad-
verse events. During treatment, patients P1, P2, and P3 were
studied twice, while P4 and P5 were studied once.
 
D-Glucose Labeling.
 
All subjects, except one (P5), were hos-
pitalized for a 7-d labeling period, when D-glucose (30 g/d; pur-
chased from Cambridge Isotope Laboratories, Inc.) was adminis-
tered intravenously while dietary carbohydrate was highly
restricted (
 

 
46 g/d).
 
Cell Count and Phenotypic Analysis of Peripheral T Cells.
 
CD4
 

 
and CD8
 

 
 cell counts were measured using TruCount System
(Becton Dickinson). Four-color flow-cytometric analysis was
performed for Ki67 expression and TdT-mediated dUTP nick-
end labeling (TUNEL) positivity. In brief, freshly isolated
 
Table I.
 
Baseline Characteristics of Study Subjects and Their Estimated Values of CD4
 
+
 
 and CD8
 
+ 
 
Lymphocyte Proliferation (p), Death (d), 
and Fractional Input from a Source (
 
U
 
)
 
Baseline values CD4
 

 
CD8
 

 
Subjects
Age
(sex)
Plasma viral 
load CD4
 

 
CD8
 

 
p
 
(95% CI)
 
d
 
(95% CI)
 
U
 
(95% CI)
 
p
 
(95% CI)
 
d
 
(95% CI)
 
U
 
(95% CI)
 
(copies/ml)
 

 
l
 

 
1
 

 
l
 

 
1
 
day
 

 
1
 
day
 

 
1
 
day
 

 
1
 
day
 

 
1
 
day
 

 
1
 
day
 

 
1
 
Controls:
C1 43 (M) - 880 562
0.005
(0.005-0.006)
0.057
(0.024-0.110)
0.044
(0.016-0.094)
0.004
(0.003-0.005)
0.076
(0.044-0.139)
0.072
(0.041-0.134)
C2 22 (F) - 992 576
0.004
(0.003-0.011)
0.064
(0.024-0.496)
0.060
(0.020-0.485)
0.002
(0.002-0.003)
0.018
(0.013-0.090)
0.016
(0.011-0.087)
C3 22 (F) - 1,366 651
0.003
(0.001-0.131)
0.013 
(0.002-10.9)
0.010
(0.000-10.7)
0.002
(0.001-0.006)
0.008
(0.002-1.36)
0.006
(0.000-1.34)
C4 22 (M) - 1,066 621
0.004
(0.003-0.005)
0.042
(0.029-0.120)
0.020
(0.013-0.065)
0.002
(0.002-0.003)
0.070
(0.016-0.196)
0.067
(0.014-0.192)
Mean
 
  
 
SE 30.0 - 1,076 603 0.004 
 

 
 0.0005 0.044 
 

 
 0.011 0.033 
 

 
 0.011 0.003 
 

 
 0.0004 0.043 
 

 
 0.017 0.040 
 

 
 0.017
Infected:
P1 38 (M) 500,000 322 806
0.033
(0.028-0.041)
0.112
(0.071-0.167)
0.077
(0.045-0.123)
0.036
(0.033-0.040)
0.065
(0.038-0.090)
0.046
(0.025-0.078)
P2 24 (M) 226,087 255 494
0.034
(0.027-0.042)
0.135
(0.086-0.255)
0.100
(0.056-0.214)
0.018
(0.015-0.022)
0.092
(0.064-0.272)
0.074
(0.049-0.249)
P3 26 (M) 7,629 323 617
0.010
(0.009-0.010)
0.042
(0.025-0.068)
0.050
(0.034-0.081)
0.010
(0.009-0.011)
0.029
(0.018-0.072)
0.031
(0.020-0.077)
P4 46 (F) 61,946 48 323
0.039
(0.036-0.047)
0.082
(0.053-0.131)
0.042
(0.016-0.086)
0.024
(0.022-0.029)
0.032
(0.024-0.059)
0.008
(0.003-0.032)
P5 38 (M) 88,997 804 1,148
0.019
(0.015-0.160)
0.306
(0.153-3.8)
0.285
(0.137-3.61)
0.029
(0.026-0.035)
0.062
(0.034-0.157)
0.022
(0.012-0.072)
P6 21 (M) 13,367 626 1,312
0.016 
(0.014-0.019)
0.151
(0.095-0.214)
0.240
(0.115-0.641)
0.024 
(0.023-0.026)
0.049
(0.038-0.067)
0.024
(0.015-0.041)
P7 36 (F) 22,410 337 1,011
0.022
(0.021-0.023)
0.077
(0.060-0.093)
0.065
(0.045-0.079)
0.017
(0.016-0.019)
0.022
(0.015-0.060)
0.011
(0.007-0.050)
Mean
 
  
 
SE 32.6 131,491 388 816 0.025 
 

 
 0.004
 
a
 
0.129 
 

 
 0.033
 
a
 
0.123 
 
 
 
0.037
 
a
 
0.023 
 

 
 0.003
 
a
 
0.050 
 

 
 0.009 0.031 
 

 
 0.009
CI, confidence interval.
 
a
 
Mean values in infected patients that are significantly different (
 
P
 
 value 
 

 
0.05 by Wilcoxon rank sum U-test) from those in normal persons.
sˆ
sˆ sˆ
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PBMCs were stained with anti–CD3-PerCP (Becton Dickinson),
anti–CD4-APC (Exalpha), and anti–CD8-PE (Dako). After
washing, cells were treated with FACS
 
®
 
 Lysing Solution (Becton
Dickinson) for 40 min at room temperature, and further stained
with anti-Ki67 (MIB-1; Beckman Coulter) in PBS with 0.5%
NP40 and 5% FCS at room temperature for 45 min. After two
washes, cells were fixed with 1% paraformaldehyde in PBS. For
TUNEL positivity, freshly isolated PBMCs were cultured over-
night without any stimulation, and then stained for cell surface
markers before detecting apoptotic cells using the In Situ Cell
Detection Kit (Roche Molecular Biochemicals). The cells were
fixed with 1% paraformaldehyde in PBS and analyzed by FACS-
Caliber™ (Becton Dickinson).
 
Viral Load Measurement.
 
Plasma viral load was measured by a
branched DNA assay (13) with a detection limit of 50 copies/ml
(Bayer Diagnostics).
 
Measurement of Deoxyadenosine Enrichment in DNA of Cell Pop-
ulations.
 
Monocytes were purified (
 

 
95% purity) using an anti-
CD14 mAb coupled to Dynabeads (Dynal). Sorting of CD3
 

 
CD4
 

 
 and CD3
 

 
CD8
 

 
 lymphocytes was carried out using Mo-
Flo (Cytomation) after staining with anti–CD3-FITC (Becton
Dickinson) together with anti–CD4-PE (Becton Dickinson) and
anti-CD8-CyChrome (BD PharMingen). The purity of the
sorted cells was 
 

 
98%. DNA was extracted from each cell prepa-
ration using QIAamp DNA Blood Mini Kit (QIAGEN), fol-
lowed by hydrolysis with nuclease P1 at 45
 

 
C overnight, snake
venom phosphodiesterase I at 37
 

 
C for 2 h, and alkaline phos-
phatase (Sigma-Aldrich) at 37
 

 
C for 1 h. Deoxyadenosine (dA)
was separated using Supelco LC-18, SPE tube (Supelco) and con-
verted to triacetylaldonitrile derivative before analysis by gas
chromatography and mass spectroscopy as described previously
(9, 10). The degree of dA enrichment was calculated using a stan-
dard curve for each experiment. Precursor enrichment was as-
sessed based on the amount of deuterium-containing glucose in
plasma, and used to convert our data into labeled DNA as de-
scribed previously (9, 10). Because dA enrichment measured at
time 
 
t
 
 is due to DNA synthesis at earlier times, for samples mea-
sured during labeling we used the average precursor enrichment
up to time 
 
t
 
 for this conversion. For samples measured after the
completion of labeling, we used the enrichment averaged over
the labeling period.
 
Mathematical Model.
 
Before D-glucose administration, we as-
sume that the number of both CD4
 

 
 and CD8
 

 
 T cells, 
 
T
 
, is de-
termined by equation 1 in Fig. 1, where 
 
s
 
 is the rate of T cell en-
try into the proliferative compartment,
 
 p 
 
is the proliferation rate
per cell, and 
 
d
 
 is the death rate per cell. During D-glucose admin-
istration when cell proliferation occurs, an unlabeled DNA
strand, U, is copied and a labeled strand, L, is created while U is
preserved. Thus, U
 
→
 
U 
 

 
 L. Similarly, when a labeled strand is
copied, L
 
→
 
L 
 

 
 L. These kinetics are described by equations 2 a
and b, where the initial amounts of unlabeled and labeled DNA
are U(0) and L(0), respectively,
 
 p 
 
and 
 
d
 
 are as in equation 1, and
the source 
 
s
 
 now has two components: an unlabled part 
 
sU and a
labeled one sL, such that s 	 sU  sL. If we assume that the system
is at steady state, the amount of DNA in the system will not
change over time, and for the first labeling the fraction of labeled
DNA is given by fL(t) 	 L(t)/[U(0)L(0)]. For the first labeling,
L(0) 	 0, since initially there is no labeled DNA. From equations
2 a and b we obtain for the fraction of labeled DNA during
D-glucose administration, , where
we have defined u as sU/U(0); thus, the source is measured rela-
tive to the total amount of DNA in the compartment. After
D-glucose administration, U→U  U and L→L  U, leading to
equations 3 a and b, where we use sU
 and sL
 for the source
terms. The primes indicate that the sources after D-glucose ad-
ministration may have changed, e.g., more of the source may
be labeled, but the total source is still s 	 sU
  sL
. From the
solution of equation 3 a, we calculate the fraction of labeled
DNA by , where
. In this equation, fL(te) represents the fraction
of labeled DNA at the time, te, that D-glucose infusion ends.
While the proliferation rate does not appear in the equations for
fL(t), it can be estimated using the steady state condition p 	 d 
s/T or in the case of DNA, p 	 d  (sU  sL)/U(0); thus,
. Because we expect , , these
two estimates of p turn out to be close to each other and in Table
I we report their mean. The initial slope of the labeling curve is
, which to a good approximation is p. When D-glucose is
fL(t) 1 sˆU d⁄–( ) 1 e dt––( )=
sˆ
fL t( ) fL te( ) sˆL′ d⁄ e
d t te–( )–
– sˆL′ d⁄+(=
sˆL′ sˆL′( ) U 0( )⁄=
p d sˆU–> sˆL sˆL′< p d sˆU sˆL′+( )–<
d sˆU–
Figure 1. A newly developed mathemat-
ical model to track labeled and unlabeled
strands of DNA before, during and after
D-glucose administration. A full explana-
tion is given in Materials and Methods.
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administered for a second or third time to the same patient, the
expressions given above for fL(t) are modified to account for any
existing labeled DNA at the start of the infusion. Also, when the
measurements of total CD4 and CD8 T cells indicate a signifi-
cant change in the population, we relax the assumption of steady
state. In this case, we used the solution of equation 1 to deter-
mine the total amount of DNA at time t to be used in the calcu-
lation of the fraction of labeled DNA. Finally, because most T
cells are in tissues, we assumed that after labeling there would be a
delay  before labeled DNA first appeared in blood. Further,
when D-glucose administration ended at time te, we also assumed
labeled DNA would continue to accumulate in the blood until
time te  . Thus, on the right hand side of the equations given
above for fL(t), t should be replaced by t  , and for 0 t  ,
fL(t) 	 0. To model monocyte kinetics, we assume no prolifera-
tion occurs in the periphery, i.e., p 	 0 in equations 1–3, and d is
interpreted as a rate of monocyte export out of blood.
Data Fitting. We fitted the appropriate equations for fL(t) to
the experimental data using a nonlinear least-square regression
method described previously (14). We calculated 95% confidence
intervals by bootstrapping (15). At each time point, we also mea-
sured the total number of CD4 and CD8 T cells, and used a
threepoint running average to smooth the data. When there was a
significant variation in cell numbers, instead of assuming steady
state we fitted simultaneously the smoothed number of T cells
and the fraction of labeled DNA. In addition, we used a jackknife
method in which zero weight was given to one outlying data
point with a disproportionate influence in the data fitting from
the labeled DNA measurements of CD4 T cells in P5 for the
first and second labeling, and the CD8 T cells in C4 and P2 for
the first labeling; however, all data points are shown below. The
average initial labeling delay, , computed using a trimmed mean,
was 0.5 d. In a few individuals who exhibited poor initial label-
ing, the data were fitted with a fixed delay of 0.5 d.
Statistical Analyses. Except where otherwise indicated, com-
parisons between groups were done using the two-tailed Wil-
coxon rank sum test, which is more appropriate for the small
sample sizes involved. Correlations, involving all the data (be-
tween 15 and 19 data points), were done using standard linear re-
gression calculations. Significance was assessed at the P 	 0.05
level.
Results
Four normal subjects and seven HIV-1-infected, treat-
ment-naive patients enrolled in our study of lymphocyte
dynamics using D-glucose as the label in what might be
considered an in-vivo pulse-chase experiment. Both groups
were of similar age (Table I). The infected patients had
baseline CD4 counts of 48–804 cells/l and plasma viral
loads of 7,629–500,000 copies/ml. All but one subject
were hospitalized for the first 7 d of the study, when
D-glucose was administered intravenously. In P5, for per-
sonal reasons, D-glucose was given for 4.3 d only. Blood
was obtained from each subject on multiple occasions, in-
cluding before, during (nearly daily), and after (every 7–10 d)
the infusion. No adverse reactions related to D-glucose ad-
ministration were noted.
Turnover of Blood Monocytes Is Very Rapid in both Healthy
Controls and HIV-1–infected Patients. To ensure that the
new labeling technique would yield reliable results, we first
examined the incorporation of deuterium into the DNA of
monocytes since their half-life (t1/2) or transit time in blood
had been defined (16). Monocytes were purified from
three normal subjects and two patients using an anti-CD14
mAb coupled to Dynabeads. DNA was then extracted
from each cell preparation, processed, and tested for the
degree of deuterium incorporation into the dA fraction us-
ing gas chromatography and mass spectroscopy. As shown
in Fig. 2, labeled DNA became detectable in blood after a
delay of 2 d. Thereafter, the fraction of labeled DNA
rose rapidly, reaching a peak of 0.60–0.85 before falling
promptly upon the cessation of D-glucose infusion. These
results were then analyzed using a simple mathematical
model that assumes monocytes label in the bone marrow
and then appear in blood with some time delay before
moving into tissues as macrophages. Fitting the data to the
model (Fig. 2) yielded a t1/2 of monocytes in blood of 2 d,
regardless of HIV-1 infection status, in close agreement
with published results (16) and thereby validating the
D-glucose labeling method (9, 10, 17).
Kinetics of both CD4 and CD8 T Cells Are Faster in
HIV-1–infected Patients than in Healthy Controls. We then
turned our attention to CD3CD4 and CD3CD8
lymphocytes that have been purified to >98% homogene-
ity by a cell sorter from each blood specimen. Again, every
cellular DNA sample was examined for deuterium incor-
poration into the dA fraction (9, 10). From the results
summarized in Fig. 3, it is readily apparent that the label-
ing and delabeling profiles in the four normal subjects
were rather uniform, with CD4 T cells showing slightly
higher levels of deuterium incorporation than CD8 T
cells. Labeled DNA became detectable with a mean time
lag of 0.5 d, and its level increased slowly during D-glu-
cose administration followed by a gradual decrease thereaf-
ter. The peak fraction of labeled DNA did not exceed 0.04
in either cell population. In contrast, the results are sub-
stantially different in seven HIV-1–infected patients who
were not on antiretroviral therapy. Their rates of rise and
Figure 2. Sequential changes in the fraction of labeled DNA in blood
monocytes. The data points are represented by symbols, and the lines
show the best fit of the data to a mathematical model. The calculated half-
lives (t1/2) for monocytes in blood are indicated.
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fall of labeled DNA were obviously greater than those ob-
served in normal controls, even in P5 who was given
D-glucose for 4.3 d. Likewise, the peak labeling was con-
sistently higher in infected individuals, with some reaching
a labeled fraction of 0.20. Interestingly, the lowest deu-
terium incorporation in infected subjects was seen in P3,
the one with the lowest viral load (Table I). There was no
consistent relationship noted when comparing labeling
profiles in CD4 versus CD8 lymphocytes. Overall, the
findings in Fig. 3 provide a qualitative impression that
lymphocyte turnover is substantially more rapid in infected
patients than in normal persons.
Proliferation and Death Rates of CD4 and CD8 T Cells
Are Elevated Several-fold in HIV-1 Infection. To obtain
quantitative estimates of CD4 and CD8 T cell turnover
from the data, we developed a new mathematical model of
lymphocyte dynamics that tracks the number of deute-
rium-labeled and unlabeled strands of cellular DNA before,
during and after D-glucose administration (Fig. 1 and Ma-
terials and Methods). Then we used the model to fit the la-
beling results generated from CD4 and CD8 T cells
from each study subject as described in Materials and
Methods. As shown in Fig. 3, a good fit of the theory to
the data was obtained in every case. In so doing, rate esti-
mates of cellular proliferation (p) and death (d) were de-
rived for both lymphocyte populations in each subject (Ta-
ble I). By comparing the mean value of p for CD4 T cells
of normal individuals (0.004/d) to that of infected patients
(0.025/d), it was clear that proliferation rates were signifi-
cantly increased (6.3-fold) in HIV-1 infection (P value
0.01). A similar comparison of mean values of d (0.044/d
vs. 0.129/d) showed CD4 lymphocyte death rates to be
significantly elevated (approximately threefold) in infected
individuals (P value 0.04). Likewise, the mean value of p
for CD8 T cells was significantly higher (7.7-fold) in
patients (0.023/d) than in normal controls (0.003/d) (P
value 0.01), although mean values of d for the two
groups were not significantly different (0.050/d vs. 0.043/
d). These quantitative estimates, therefore, validate the
qualitative impression above that HIV-1 infection results in
a faster turnover of both CD4 and CD8 T cells.
Source of CD4 T Cells May Increase in HIV-1 Infection.
Note that in Table I the data fitting also provided esti-
mates for , which is, to a good approximation, the frac-
tion of T cells in the proliferating compartment input
from a source per day (Fig. 1, references 18 and 19). The
mean value of   for CD4 lymphocytes in infected pa-
tients (0.123/d) was significantly higher (P value 0.05)
than in normal persons (0.033/d); however, the mean val-
ues of   for CD8 lymphocytes were not very different
(0.031/d vs. 0.040/d) between the two groups. There was
no evidence to suggest that HIV-1 infection results in a
decrease of CD4 T cells coming from a source. As we
have discussed previously (7, 18, 19), this source could be
the thymus or merely a population of resting or slowly di-
viding lymphocytes that upon activation would undergo
rapid clonal expansion and enter the pool of cells acquir-
ing label during the experiment. A model that includes
separate populations of resting and proliferating T cells can
also fit the data and supports the concept that the source
corresponds to activation of resting cells (unpublished
data).
sˆU
sˆU
sˆU
Figure 3. Sequential changes
in the fraction of labeled DNA in
blood T lymphocytes. The data
of healthy controls (C1–C4) ver-
sus HIV-1–infected patients (P1–
P7) are shown in each graph.
The period of D-glucose admin-
istration is indicated by a box
(top left corner). The data points
are represented by symbols, and
the lines show the best fit of the
data to a mathematical model.
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Enhanced Turnover of both CD4 and CD8 T Cells in
HIV-1 Infection Decreases upon Antiretroviral Therapy. Five
of the infected patients were reevaluated to assess the im-
pact of successful antiretroviral therapy on lymphocyte dy-
namics. A potent four-drug regimen was initiated in P1
through P5 several weeks after the completion of their first
labeling study. As shown in Fig. 4 A, plasma viremia
dropped precipitously in each case, eventually reaching un-
detectable levels in those patients treated beyond 150 d. At
the same time, the CD4 T cell numbers of these patients
showed an increasing trend (Fig. 4 A). The second episode
of D-glucose labeling was carried out in these five patients
beginning on days 35–77 of treatment. P4 and P5 left the
study after finishing the second study, whereas P1, P2, and
P3 went on to have the third episode of D-glucose labeling
starting on days 245–375 of treatment when plasma viral
load was persistently undetectable save for one transient
“blip” in P2.
The results of the sequential D-glucose labeling studies
are presented case by case in Fig. 4 B. In all but one pa-
tient (P3), the second labeling yielded slower rates of deu-
terium incorporation and loss in CD4 and CD8 lym-
phocytes as compared with the first labeling. Similarly, the
peak values for the fraction of labeled DNA were consis-
tently lower for the second episode, despite having higher,
non-zero baseline values (0.005–0.05) that were attribut-
able to the low-level persistence of label from the first
study. In P1 and P2, even slower rates of rise and fall of la-
beled DNA were evident for the third labeling episode, as
were the peak values. In P3, the labeling profiles in CD4
T cells were indistinguishable for the three longitudinal
studies, although a slight reduction in labeling was noted
in CD8 T cells for the second and third episodes. It
should be pointed out, however, that this patient had the
lowest plasma viral load before treatment (Table I) and his
first labeling profile was only modestly higher than those
of normal individuals (Fig. 3). Thus, in this case, only
minimal reductions in labeling could be expected for anti-
retroviral therapy. The results of P3 notwithstanding, the
overall changes in labeling profiles during effective treat-
ment suggest that turnover rates for both CD4 and
CD8 lymphocytes decline, promptly and substantially, as
HIV-1 replication is suppressed.
When the mathematical model was used to analyze the
results of these sequential studies during treatment, a good
fit to the data was observed once again (Fig. 4 B). Esti-
mates of p and d for CD4 and CD8 lymphocytes were
then derived for each episode of labeling. Fig. 4 C shows
that substantial decreases in both p and d for both T cell
populations were seen by the second study, 5–11 wk
into antiretroviral therapy. Further reductions in these
turnover rates were noted for the third study of P1 and P2,
46–53 wk into treatment. The decreases in p reached
statistical significance by the paired Student’s t test for both
CD4 and CD8 populations (P values of 0.03 and 0.006,
respectively), but due to the sample size only approached
significance by the more appropriate Wilcoxon signed
rank test (0.0625, the smallest two-tailed P value obtain-
able with 5 data points). The decreases in d were not statis-
tically significant. Nevertheless, these quantitative findings
again confirm the qualitative impression that the height-
ened T lymphocyte turnover in HIV-1 infection is nor-
malized, albeit incompletely, by effective antiretroviral
therapy for about a year.
Proliferation Rates of CD4 and CD8 T Cells Correlate
with Ki67 and TUNEL Expression. We next compared
the values of p and d derived for all subjects from the three
labeling studies to the expression of two lymphocyte mark-
ers: Ki67, a nuclear antigen expressed exclusively in cells in
late G1, S, G2, and M phases of the cell cycle (20), and
TUNEL, an indicator of apoptosis (21). As shown in Fig. 5
A, there was a direct correlation between the value of p and
the fraction of cells positive for Ki67 or TUNEL. These
correlations, seen in both CD4 and CD8 lymphocytes,
were strong (correlation coefficients between 0.79 and
0.91) and statistically significant (P values 0.002). The
value of d, however, was only weakly correlated with these
markers (P value 0.05), and in CD8 T cells the correla-
tion between d and TUNEL was not significant (data not
shown). Nevertheless, these results suggest that Ki67 and
TUNEL expression in blood cells could serve as simple and
reasonably reliable surrogate markers for lymphocyte pro-
liferation in vivo.
Kinetic Parameters Correlate Positively with Plasma Viral
Loads, and Inversely with CD4 Cell Counts. We also com-
pared levels of Ki67 and TUNEL expression, as well as
values of p and d, to the CD4 T cell count and plasma
viral load of each subject at the initiation of each labeling
study, which we term baseline measurements (Fig. 5 B).
An inverse correlation between the baseline CD4 lym-
phocyte count and the fraction of CD4 or CD8 T cells
positive for Ki67 or TUNEL, was evident, as was re-
ported (5, 22). An inverse relationship was also noted for
p, but not for d (data not shown). On the other hand, a
direct correlation was observed between the baseline
plasma viral load and each of the following parameters: p,
Ki67 expression, and TUNEL positivity. A direct correla-
tion was also found between d and baseline viral load, but
only in the CD4 T cell population (r 	 0.61, P value 	
0.016, data not shown). That such a correlation was not
found for CD8 cells suggests that the rate of death of
proliferating CD8 T cells was the same in uninfected
and infected subjects with different viral loads. Moreover,
because the linear regression lines for CD8 lymphocytes
are nearly parallel in Fig. 5 B, it appears that the parame-
ters, p, Ki67, and TUNEL, are coupled not only to the
amount of HIV-1 replication in vivo, but also to each
other. Note that such a relationship also holds true for p
and Ki67 expression in CD4 lymphocytes. However,
the linear regression line for TUNEL positivity takes on a
significantly different slope (P value  0.02), indicating
that the coupling of cellular proliferation to apoptosis is
distinguishable between CD4 and CD8 T cells. This
difference may be due to the preferential infection and
elimination of CD4 lymphocytes by nonapoptotic
mechanisms.
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Figure 4. Comparison of T cell kinetics before and during antiretroviral therapy. (A) Changes in viral load as well as CD4 and CD8 lymphocyte
counts during treatment. The data from each patient are represented by a unique symbol. The periods of repeat D-glucose labeling studies are indicated
by rectangular boxes marked by each patient’s identification number followed by the episode of labeling. (B) Fraction of labeled DNA in CD4 and
CD8 lymphocytes from P1–P5 during the first (pretreatment) (), second (gray square), and third () episodes of labeling. The duration of D-glucose
administration is indicated by a box in each graph. Again, the data points are represented by symbols, and the lines show the best fit of the data to the
mathematical model. Note that the fraction of labeled DNA on day 0 in the second or third episode is not zero because of residual label from the previ-
ous labeling episode. (C) Changes in the estimated values of p (proliferation rate) and d (death rate) with antiretroviral therapy.
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Discussion
The dynamics of lymphocyte turnover in HIV-1 infec-
tion remained unresolved despite numerous studies over
the past 6 y. We addressed this controversy by conducting a
clinical study to directly measure rates of cellular prolifera-
tion and death by adapting a recently developed technique
using the stable isotope deuterium incorporated into glu-
cose to label the DNA of dividing cells (9, 10, 17). Impor-
tant modifications in our approach included the extension
of D-glucose infusion to 7 d to increase the chance of cap-
turing rare events, as well as the frequent sampling (7–12
data points per study) of blood to carefully define the pro-
file of label uptake and loss. In addition, a mathematical
model was developed to interpret the results quantitatively.
We now report findings that conclusively demonstrate
heightened lymphocyte turnover in HIV-1 infection. As
shown in Table I, compared with normal controls, the
mean death rate of CD4 T cells was elevated by 3.0-
fold, which was somewhat balanced by a 6.3-fold increase
in the mean proliferation rate and a 3.6-fold increase in the
mean rate of cell infusion from a source (see Discussion be-
low). In CD8 T cells, the mean death rate was minimally
higher (1.2-fold) in infected patients, which was accom-
panied by a 7.7-fold rise in mean proliferation rate and a
small decrease in the mean source rate. Even though we
have small sample sizes, these results are in good agreement
with data from direct labeling studies in infected humans
(10, 17) or SIV-infected monkeys (7, 8), or from indirect
assessments of cellular proliferation (5, 6, 23–25).
The model that the primary effect of HIV-1/SIV infec-
tion is to increase T cell destruction and that the major
consequence of antiretroviral therapy is to decrease that de-
struction was recently called into question (10–12, 17).
Lymphocyte turnover was reported to fall only after 12–18
mo of effective treatment (17), but not after 12 wk (10,
17). These results thus raised the specter that the major de-
fect in lymphocyte dynamics during HIV-1 infection is a
block in the regenerative capacity. In this study, we have
reexamined this important issue by carrying out longitudi-
nal labeling studies in patients before and during successful
treatment with drug regimens that are not known to have
any direct effects on lymphocytes. It is clear from results
shown in Fig. 4 that lymphocyte turnover rates decreased
substantially by 5–11 wk into therapy. There was no evi-
dence in any case to indicate that these rates increased as
HIV-1 replication came under control. With continuation
of antiretroviral agents for 1 y, lymphocyte turnover rates
dropped further to values only slightly higher than those of
normal subjects.
While the small sample size did not allow us to statisti-
cally test if the proliferation rates are identical in controls
and in infected individuals after long-term therapy, the re-
gression line of p versus viral load in Fig. 5 B suggests that
with continued potent therapy the proliferation rates will
normalize. This finding is in reasonable agreement with
D-glucose-labeling data from two patients treated for 18 mo
(17), as well as with those from surrogate measurements
(24, 25). However, our results cannot be reconciled with
those that showed unchanged (17) or increased (10) lym-
phocyte turnover with short-term antiretroviral therapy. A
possible explanation may be that the previous conclusion
was based on a cross-sectional comparison of treated and
untreated patient groups that are not well matched clini-
cally. Also, if we only look at single time points after infu-
sion, as was done in previous studies (10, 17), there are sev-
eral cases where the fraction of labeled DNA is higher in
our treated patients than in the nontreated patients. But
such a cursory examination is inadequate in accurately cap-
turing the labeling profile of a cell population of interest.
Thus, given the strength of our new longitudinal data,
Figure 5. Correlation among parameters. (A) Correlation of the frac-
tion of CD4 and CD8 lymphocytes expressing Ki67 antigen or
TUNEL with p, the lymphocyte proliferation rate. Significant correla-
tions were observed between values of p and fractions of Ki67 CD4 T
cells (r 	 0.91, P value 0.00001) or CD8 T cells (r 	 0.90, P value
0.00001), as well as between values of p and fractions of TUNEL
CD4 T cells (r = 0.79, P value 	 0.00006) or CD8 T cells (r 	 0.87, P
value 0.00001). Note that these regression lines are parallel in CD8
lymphocytes (P value 	 0.86), but not in CD4 lymphocytes (P value 	
0.0017). (B) Significant correlation between baseline CD4 T cell count
or plasma viral load and values of p, fraction of Ki67 cells, or fraction of
TUNEL cells in both CD4 and CD8 cell populations (P values
0.05). Results of patients with undetectable plasma viral load are plotted
as of 50 copies/ml (detection limit).
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there should be little doubt that a model of high lympho-
cyte turnover and normalization upon treatment correctly
depicts the situation in HIV-1 infection.
Some may continue to argue that the rapid turnover of
lymphocytes in this disease is accompanied by a dimin-
ished fractional regenerative capacity as well. But one must
keep in mind that such a scenario would lead to a constant
loss of lymphocytes, and could not possibly account for
the prolonged quasisteady-state in T cell counts seen in
most cases of HIV-1 infection. To maintain a stable lym-
phocyte count from day to day, a rapid cell death rate
must be balanced by an equally rapid replacement rate. In
fact, such steady-state considerations have long argued
against regenerative failure as the principal cause of CD4
lymphocyte depletion seen in AIDS, because it necessarily
implies a slower death rate for the cell population. That
CD4 T cells would have a longer than normal survival
time in the presence of rampant HIV-1 replication is diffi-
cult to fathom.
Several of our findings warrant additional comments.
First, when the mean values of p in Table I were trans-
formed into doubling times (t2 	 ln2/p), averages of 173
and 231 d were obtained in normal persons for CD4 and
CD8 T cells, respectively. These numbers are in line with
prior estimates in normal monkeys (7, 8) and determina-
tions of intermitotic intervals based on the persistence of
chromosomal defects in human T lymphocytes (26, 27).
Mean values of t2 in infected patients were, as expected,
considerably shorter for both CD4 (28 d) and CD8
lymphocytes (31 d). When the mean values of d were sim-
ilarly transformed, an average t1/2 of 16 d was obtained for
both T cell populations in normal individuals. In infected
patients, a mean t1/2 of 6 d was noted for CD4 lympho-
cytes, whereas a mean t1/2 of 14 d was observed for CD8
lymphocytes. As these survival times are strikingly short, it
is important to point out that they refer only to lympho-
cytes that are amenable to study by the D-glucose labeling
technique. But it is clear from our model (Fig. 1) that
there could exist a source population, such as resting cells,
that could input cells into the compartment under study
(7, 18, 19). Since the relative proportion of these two sep-
arate cellular compartments is not known, it would be in-
appropriate to apply these short t1/2’s to the entire CD4
or CD8 T cell population to derive absolute rates of lym-
phocyte death per day. In fact, it should be emphasized
that only fractional turnover rates are presented and dis-
cussed in this study. Any comparison with absolute rates of
lymphocyte proliferation and death must be done cau-
tiously. A further source of heterogeneity in the CD4
and CD8 T cell populations that is not taken into consid-
eration is their subdivision into naive and memory popula-
tions. Memory populations turnover more rapidly than
naive populations (17, 26, 27) and thus one might specu-
late that the kinetic parameters measured in this short-term
labeling study are more indicative of memory than naive
cells. However, because the fractions of naive and memory
cells were not measured and since such fractions vary
among individuals and change under treatment, we have
refrained from making any such interpretations of our
data.
Second, HIV-1 infection is associated with a 6-8–fold
elevation in the mean values of p in both CD4 and
CD8 lymphocytes (Table I), consistent with changes seen
in SIV infection of macaques (7, 8). A greater increase in
the mean value of d, however, was found for CD4 T
cells (approximately threefold) than in CD8 T cells
(1.2-fold). These findings show that while there are sim-
ilarities in the HIV-1–induced generalized activation of
both lymphocyte populations, as discussed previously (7,
8, 28), there are also discernible differences in the kinetics
of cell death in this study, with the death rate being signif-
icantly faster in CD4 lymphocytes than in CD8 lym-
phocytes (P value 0.02). This conclusion is supported by
the results presented in Fig. 5 B. In the CD8 population,
both cellular proliferation (p and Ki67 expression) and
apoptosis (TUNEL positivity ex vivo) are directly propor-
tional to the degree of virus replication in vivo. On the
other hand, in the CD4 population, the relationship of
viral load to apoptosis appears to be different, although the
relationship to cellular proliferation remains the same as
that in CD8 T cells. Thus, the combination of a higher
death rate (Table I) and a proportionally lower frequency
of apoptosis in CD4 versus CD8 T cells (Fig. 5 B) sug-
gests that many CD4 lymphocytes may be dying by a
pathway other than generalized T cell activation. We
speculate that there is a sizeable component of nonapop-
totic virus-mediated cell killing.
Third, the labeling profiles in Figs. 3 and 4 B showed
that labeled lymphocytes appeared in blood after only a
short lag time. In fact, a detailed analysis using our mathe-
matical model revealed that the average lag was 0.5 d
(data not shown). Moreover, every determination made on
samples taken at the time point immediately after the end
of D-glucose administration demonstrated a drop in label
incorporation, including timepoints taken only 2–3 d after
the infusion period (P5 and P7 in Fig. 3). Taken together,
these results argue for rapid transport and equilibration of T
lymphocytes between blood and tissue, where much of the
cellular proliferation takes place. Models that assume a long
delay (10, 17) would yield misleading conclusions. Further-
more, due to this rapid equilibration, the parameter d
should reflect true loss of labeled T cells and not simply
transport out of the blood as was the case for monocytes.
Lastly, we note that the labeling profiles in Figs. 3 and 4
B cannot be fitted by analytical models (10, 17) that as-
sume p 	 d and s 	 0 in Fig. 1 (data not shown). Infusion
of lymphocytes from a source is in fact required. As shown
in Table I, a significant increase in the source rate for
CD4 T cells is seen with HIV-1 infection. The thymus is,
of course, one such possible source. Several studies have
assessed the number of recent thymic emigrants in the
blood of HIV-1–infected persons by measuring the con-
centration of T cell receptor excision circles (TREC) (29–
31) as a surrogate. Abnormally low TREC numbers were
found in all infected individuals in one study (29), but only
in a subset of patients in another study (30). Nevertheless, a
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low TREC content does not necessarily imply a decreased
thymic output, since TREC could be diluted by enhanced
lymphocyte proliferation or lost by cell death (30, 31).
Thus, it remains possible that the thymus is serving as one
source of lymphocytes in our model. However, given that
we find that the source rates for CD8 cells are slightly de-
creased by HIV-1 infection, while CD4 T cell source
rates are increased 3.6-fold (Table I), we favor the hypoth-
esis that a population of resting or slowly dividing T cells
in secondary lymphoid tissues is acting as an additional
source (7, 19, manuscript in preparation). With infrequent
cell divisions, such lymphocytes are essentially invisible to
our short-term labeling study. Upon activation, these lym-
phocytes would undergo clonal expansion and enter the
pool of cells acquiring label during the experiment,
thereby appearing like a source. With this interpretation,
the parameter p that we have estimated could then be in-
terpreted as the average proliferation rate of the resting and
activated populations and hence well approximated by the
fraction of activated cells times the proliferation rate of an
activated cell. Since we only follow the loss of labeled
DNA, the estimated death rate, d, would then be inter-
preted as the death rate of cells that have acquired label,
i.e., activated cells. This would also explain why in the
CD8 T cell population there is no difference between
death rates of controls and infected individuals, since in
both cases we are estimating d for activated cells, and why
the cellular half-lives that we have computed from the esti-
mates of d are so short.
In summary, our new findings document the increased
turnover of T cells in HIV-1 infection, and reject the notion
of a global lymphocyte regenerative defect in this disease.
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